Trial Profile
Single arm, open label, signal seeking, phase IIa trial of the activity of vismodegib in patients with tumours harbouring PTCH1 or SMO mutations
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Vismodegib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Acronyms MoST Addendum 4
- 19 Mar 2019 Status changed from not yet recruiting to recruiting.
- 24 May 2018 Planned initiation date changed from 1 Jun 2018 to 1 Sep 2018.
- 23 Feb 2018 New trial record